| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 41 | 2025 | 1128 | 9.810 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 43 | 2024 | 427 | 7.660 |
Why?
|
| Carcinoma, Hepatocellular | 24 | 2024 | 1000 | 4.770 |
Why?
|
| Hepatitis C, Chronic | 19 | 2023 | 373 | 4.540 |
Why?
|
| Liver Neoplasms | 25 | 2024 | 1410 | 4.290 |
Why?
|
| Hepatitis C | 15 | 2023 | 389 | 4.220 |
Why?
|
| End Stage Liver Disease | 21 | 2024 | 203 | 3.850 |
Why?
|
| Liver Diseases, Alcoholic | 10 | 2023 | 59 | 3.460 |
Why?
|
| Liver Cirrhosis | 34 | 2025 | 941 | 2.650 |
Why?
|
| Antiviral Agents | 18 | 2023 | 824 | 2.630 |
Why?
|
| Hepacivirus | 13 | 2023 | 273 | 2.500 |
Why?
|
| Waiting Lists | 13 | 2024 | 244 | 2.170 |
Why?
|
| Tissue and Organ Procurement | 7 | 2025 | 247 | 2.170 |
Why?
|
| Tissue Donors | 10 | 2025 | 523 | 2.070 |
Why?
|
| Fatty Liver | 10 | 2025 | 215 | 2.050 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 384 | 1.950 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 395 | 1.950 |
Why?
|
| Nutrition Surveys | 23 | 2025 | 312 | 1.830 |
Why?
|
| Gastrointestinal Diseases | 3 | 2021 | 361 | 1.560 |
Why?
|
| United States | 61 | 2025 | 11718 | 1.510 |
Why?
|
| Betacoronavirus | 5 | 2020 | 305 | 1.440 |
Why?
|
| Hepatitis, Alcoholic | 5 | 2025 | 34 | 1.390 |
Why?
|
| Humans | 145 | 2025 | 133775 | 1.260 |
Why?
|
| Hospitalization | 13 | 2024 | 1900 | 1.170 |
Why?
|
| Pandemics | 15 | 2024 | 1189 | 1.170 |
Why?
|
| Risk Factors | 37 | 2025 | 11127 | 1.140 |
Why?
|
| Retrospective Studies | 45 | 2025 | 17433 | 1.090 |
Why?
|
| Graft Survival | 9 | 2025 | 557 | 1.070 |
Why?
|
| Organ Transplantation | 2 | 2020 | 186 | 1.060 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 86 | 1.050 |
Why?
|
| Adult | 57 | 2025 | 31894 | 1.040 |
Why?
|
| Prevalence | 22 | 2025 | 2669 | 0.970 |
Why?
|
| Middle Aged | 55 | 2025 | 29318 | 0.950 |
Why?
|
| Alcohol Drinking | 3 | 2023 | 387 | 0.900 |
Why?
|
| Elasticity Imaging Techniques | 6 | 2024 | 139 | 0.890 |
Why?
|
| Liver | 11 | 2025 | 1877 | 0.890 |
Why?
|
| Mortality | 4 | 2021 | 262 | 0.860 |
Why?
|
| Transplant Recipients | 3 | 2021 | 227 | 0.840 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2023 | 50 | 0.810 |
Why?
|
| Liver Failure | 3 | 2017 | 91 | 0.790 |
Why?
|
| Length of Stay | 8 | 2025 | 1388 | 0.780 |
Why?
|
| Male | 66 | 2025 | 65895 | 0.780 |
Why?
|
| Cause of Death | 15 | 2025 | 507 | 0.780 |
Why?
|
| Proton Pump Inhibitors | 3 | 2020 | 285 | 0.770 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 478 | 0.750 |
Why?
|
| Coinfection | 2 | 2023 | 182 | 0.730 |
Why?
|
| Drug Overdose | 2 | 2020 | 75 | 0.730 |
Why?
|
| Aged | 33 | 2025 | 21691 | 0.730 |
Why?
|
| Female | 65 | 2025 | 71655 | 0.720 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2020 | 87 | 0.710 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 35 | 0.640 |
Why?
|
| Gastrectomy | 2 | 2017 | 103 | 0.620 |
Why?
|
| Liver Diseases | 5 | 2023 | 391 | 0.620 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 243 | 0.620 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 24 | 0.600 |
Why?
|
| Probiotics | 1 | 2021 | 229 | 0.600 |
Why?
|
| DNA, Viral | 2 | 2018 | 500 | 0.560 |
Why?
|
| Severity of Illness Index | 12 | 2025 | 3098 | 0.550 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 14 | 0.550 |
Why?
|
| Diabetes Mellitus | 6 | 2024 | 936 | 0.540 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 58 | 0.530 |
Why?
|
| Portal Vein | 1 | 2017 | 95 | 0.530 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 239 | 0.520 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 6 | 0.520 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1090 | 0.520 |
Why?
|
| Time Factors | 13 | 2024 | 6585 | 0.510 |
Why?
|
| Transplants | 1 | 2016 | 37 | 0.510 |
Why?
|
| Secondary Prevention | 1 | 2017 | 225 | 0.500 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3167 | 0.490 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 168 | 0.480 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 2091 | 0.470 |
Why?
|
| Health Care Costs | 4 | 2024 | 407 | 0.470 |
Why?
|
| Hospital Costs | 1 | 2016 | 187 | 0.460 |
Why?
|
| HIV Infections | 3 | 2025 | 2072 | 0.450 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 295 | 0.450 |
Why?
|
| Databases, Factual | 8 | 2022 | 1243 | 0.440 |
Why?
|
| Proportional Hazards Models | 8 | 2025 | 1488 | 0.440 |
Why?
|
| Hepatic Encephalopathy | 4 | 2023 | 88 | 0.430 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 824 | 0.420 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 271 | 0.410 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2023 | 45 | 0.400 |
Why?
|
| HIV | 2 | 2025 | 195 | 0.400 |
Why?
|
| Risk Assessment | 13 | 2024 | 3713 | 0.400 |
Why?
|
| Treatment Outcome | 17 | 2025 | 13011 | 0.400 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 121 | 0.400 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2024 | 21 | 0.400 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2025 | 73 | 0.390 |
Why?
|
| Young Adult | 13 | 2025 | 9883 | 0.380 |
Why?
|
| Patient Readmission | 3 | 2020 | 418 | 0.370 |
Why?
|
| Laparoscopy | 1 | 2017 | 514 | 0.370 |
Why?
|
| Cross-Sectional Studies | 11 | 2025 | 3743 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 1145 | 0.360 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 7200 | 0.350 |
Why?
|
| Health Policy | 2 | 2025 | 233 | 0.340 |
Why?
|
| Incidence | 7 | 2025 | 3410 | 0.330 |
Why?
|
| Registries | 4 | 2019 | 1571 | 0.300 |
Why?
|
| Hypothyroidism | 2 | 2020 | 100 | 0.290 |
Why?
|
| Inpatients | 4 | 2020 | 541 | 0.290 |
Why?
|
| Health Status Disparities | 3 | 2020 | 249 | 0.280 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 282 | 0.270 |
Why?
|
| Recurrence | 3 | 2021 | 1470 | 0.270 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 688 | 0.260 |
Why?
|
| Cohort Studies | 7 | 2024 | 5195 | 0.240 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 139 | 0.240 |
Why?
|
| Preoperative Period | 3 | 2020 | 93 | 0.230 |
Why?
|
| Cholangitis | 1 | 2025 | 39 | 0.230 |
Why?
|
| Troponin | 1 | 2025 | 78 | 0.230 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 66 | 0.230 |
Why?
|
| Organ Preservation | 1 | 2025 | 50 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 757 | 0.230 |
Why?
|
| Pulse Wave Analysis | 1 | 2024 | 51 | 0.220 |
Why?
|
| Donor Selection | 1 | 2024 | 58 | 0.220 |
Why?
|
| Hepatitis A | 1 | 2024 | 32 | 0.220 |
Why?
|
| Depression | 3 | 2023 | 1359 | 0.220 |
Why?
|
| Republic of Korea | 1 | 2024 | 52 | 0.220 |
Why?
|
| Perfusion | 1 | 2025 | 214 | 0.210 |
Why?
|
| Telemedicine | 2 | 2023 | 500 | 0.210 |
Why?
|
| Age Distribution | 3 | 2019 | 444 | 0.210 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 30 | 0.210 |
Why?
|
| Vascular Stiffness | 1 | 2024 | 80 | 0.210 |
Why?
|
| Policy | 1 | 2023 | 37 | 0.200 |
Why?
|
| Adolescent | 6 | 2024 | 20541 | 0.200 |
Why?
|
| California | 2 | 2020 | 143 | 0.200 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 341 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 1070 | 0.190 |
Why?
|
| Cost of Illness | 2 | 2021 | 276 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2025 | 402 | 0.190 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 606 | 0.190 |
Why?
|
| Integrases | 1 | 2023 | 163 | 0.190 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 121 | 0.190 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 27 | 0.180 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2023 | 80 | 0.180 |
Why?
|
| Hepatitis B | 1 | 2023 | 173 | 0.180 |
Why?
|
| Prebiotics | 1 | 2021 | 29 | 0.180 |
Why?
|
| Alcohol Abstinence | 1 | 2021 | 17 | 0.180 |
Why?
|
| Viremia | 1 | 2022 | 135 | 0.180 |
Why?
|
| Cholestasis | 1 | 2023 | 158 | 0.180 |
Why?
|
| Military Personnel | 1 | 2023 | 203 | 0.180 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 15 | 0.180 |
Why?
|
| Health Care Rationing | 1 | 2021 | 63 | 0.180 |
Why?
|
| Hypernatremia | 1 | 2021 | 33 | 0.180 |
Why?
|
| Tacrolimus | 1 | 2021 | 108 | 0.180 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 31 | 0.170 |
Why?
|
| Age Factors | 4 | 2024 | 2990 | 0.170 |
Why?
|
| Hyponatremia | 1 | 2021 | 76 | 0.170 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 322 | 0.170 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 142 | 0.170 |
Why?
|
| Prediabetic State | 1 | 2021 | 63 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2021 | 56 | 0.170 |
Why?
|
| Peritonitis | 2 | 2017 | 80 | 0.170 |
Why?
|
| Exercise | 3 | 2021 | 869 | 0.170 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 19 | 0.170 |
Why?
|
| Biliary Atresia | 1 | 2023 | 205 | 0.170 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 81 | 0.170 |
Why?
|
| Dysbiosis | 1 | 2021 | 145 | 0.170 |
Why?
|
| Acute Kidney Injury | 2 | 2025 | 703 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2021 | 181 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1492 | 0.160 |
Why?
|
| Thyroid Gland | 1 | 2020 | 112 | 0.160 |
Why?
|
| Causality | 1 | 2019 | 94 | 0.160 |
Why?
|
| Methadone | 1 | 2020 | 126 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1313 | 0.160 |
Why?
|
| Entamoebiasis | 1 | 2019 | 3 | 0.160 |
Why?
|
| Entamoeba histolytica | 1 | 2019 | 14 | 0.150 |
Why?
|
| Fibrosis | 4 | 2024 | 462 | 0.150 |
Why?
|
| Phenols | 1 | 2019 | 57 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 33 | 0.150 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 463 | 0.150 |
Why?
|
| Colonic Diseases | 1 | 2019 | 38 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 244 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2019 | 68 | 0.150 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 54 | 0.150 |
Why?
|
| Disease Progression | 6 | 2022 | 2240 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2019 | 331 | 0.140 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 31 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 365 | 0.140 |
Why?
|
| Rifamycins | 1 | 2017 | 22 | 0.140 |
Why?
|
| Ascites | 3 | 2025 | 105 | 0.140 |
Why?
|
| Licensed Practical Nurses | 1 | 2017 | 1 | 0.140 |
Why?
|
| Bacterial Infections | 2 | 2017 | 327 | 0.140 |
Why?
|
| Sofosbuvir | 1 | 2017 | 21 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 694 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 326 | 0.130 |
Why?
|
| Nutritional Support | 1 | 2017 | 57 | 0.130 |
Why?
|
| Hepatorenal Syndrome | 1 | 2017 | 32 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 34 | 0.130 |
Why?
|
| Thrombophilia | 1 | 2017 | 41 | 0.130 |
Why?
|
| Carbamates | 1 | 2017 | 68 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 201 | 0.130 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2016 | 3 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 732 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2020 | 251 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 284 | 0.130 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 94 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5468 | 0.130 |
Why?
|
| Income | 1 | 2016 | 140 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 211 | 0.120 |
Why?
|
| Heparin | 1 | 2017 | 225 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3655 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2017 | 326 | 0.120 |
Why?
|
| Educational Status | 1 | 2016 | 298 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1210 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2902 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2016 | 145 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2022 | 1596 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 175 | 0.120 |
Why?
|
| Health Resources | 1 | 2016 | 126 | 0.120 |
Why?
|
| Heterozygote | 1 | 2017 | 720 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 320 | 0.110 |
Why?
|
| Malnutrition | 1 | 2017 | 218 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 253 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 770 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 648 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2016 | 398 | 0.110 |
Why?
|
| Survival Rate | 4 | 2020 | 2217 | 0.110 |
Why?
|
| Allografts | 2 | 2025 | 198 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 604 | 0.100 |
Why?
|
| Veterans | 1 | 2023 | 1779 | 0.090 |
Why?
|
| Kidney | 1 | 2019 | 1419 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 485 | 0.090 |
Why?
|
| Decision Making | 1 | 2016 | 700 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 914 | 0.090 |
Why?
|
| Morbidity | 2 | 2023 | 256 | 0.090 |
Why?
|
| Comorbidity | 3 | 2023 | 1624 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2023 | 6595 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 54 | 0.080 |
Why?
|
| Medicaid | 2 | 2023 | 254 | 0.080 |
Why?
|
| Prognosis | 4 | 2023 | 5074 | 0.080 |
Why?
|
| ROC Curve | 2 | 2023 | 610 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 105 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 560 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1215 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2018 | 1255 | 0.080 |
Why?
|
| Censuses | 2 | 2019 | 11 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2174 | 0.080 |
Why?
|
| Child | 3 | 2024 | 25780 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 1387 | 0.070 |
Why?
|
| Biopsy | 2 | 2023 | 1302 | 0.070 |
Why?
|
| Linear Models | 2 | 2020 | 722 | 0.070 |
Why?
|
| SEER Program | 2 | 2021 | 224 | 0.070 |
Why?
|
| Quality of Life | 1 | 2017 | 2150 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2024 | 1004 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2024 | 1715 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2021 | 1338 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2570 | 0.060 |
Why?
|
| Renal Dialysis | 2 | 2025 | 888 | 0.060 |
Why?
|
| Logistic Models | 2 | 2020 | 1908 | 0.060 |
Why?
|
| Prednisolone | 1 | 2025 | 79 | 0.060 |
Why?
|
| Primary Graft Dysfunction | 1 | 2025 | 26 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 562 | 0.060 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 30 | 0.060 |
Why?
|
| Agent Orange | 1 | 2023 | 3 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2025 | 124 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1199 | 0.050 |
Why?
|
| Neoplasms | 1 | 2019 | 3029 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2023 | 795 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2297 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2023 | 103 | 0.050 |
Why?
|
| Food Supply | 1 | 2024 | 101 | 0.050 |
Why?
|
| Mutation | 1 | 2017 | 6295 | 0.050 |
Why?
|
| Hand Strength | 1 | 2022 | 60 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 106 | 0.050 |
Why?
|
| Living Donors | 1 | 2023 | 118 | 0.050 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2023 | 74 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 170 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 86 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 91 | 0.050 |
Why?
|
| Acute Disease | 1 | 2025 | 1191 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2022 | 197 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 134 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 558 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2025 | 629 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 124 | 0.040 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 8 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 489 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 309 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 86 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 144 | 0.040 |
Why?
|
| Obesity | 2 | 2024 | 2433 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 36443 | 0.040 |
Why?
|
| Death Certificates | 1 | 2019 | 11 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 162 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2023 | 707 | 0.040 |
Why?
|
| Paromomycin | 1 | 2019 | 4 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 92 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2018 | 60 | 0.040 |
Why?
|
| Weight Loss | 1 | 2023 | 516 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 105 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 42 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 835 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 413 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 46 | 0.040 |
Why?
|
| Testosterone | 1 | 2023 | 618 | 0.040 |
Why?
|
| Myositis | 1 | 2019 | 102 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 479 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 13 | 0.030 |
Why?
|
| Patient Portals | 1 | 2017 | 20 | 0.030 |
Why?
|
| Computer Security | 1 | 2017 | 29 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 99 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2020 | 415 | 0.030 |
Why?
|
| Advanced Practice Nursing | 1 | 2016 | 8 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 138 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 249 | 0.030 |
Why?
|
| Confidentiality | 1 | 2017 | 106 | 0.030 |
Why?
|
| Safety-net Providers | 1 | 2017 | 62 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 254 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2016 | 129 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2018 | 248 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 284 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 296 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 549 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 312 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 375 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 571 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3431 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 541 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 461 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1497 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 727 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 453 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 474 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 1043 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 1439 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 734 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1415 | 0.030 |
Why?
|
| Anxiety | 1 | 2020 | 991 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1717 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2016 | 400 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1338 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1974 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1734 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 542 | 0.020 |
Why?
|
| Diet | 1 | 2020 | 1191 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8593 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13175 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 14810 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7545 | 0.010 |
Why?
|